JCO:北大肿瘤医院3期试验揭示多科室联合治疗转移性胃癌的临床获益

2021-01-12 Nebula MedSci原创

胃食管癌(EGC)是全球癌症相关死亡的第二大主要原因。当下,迫切需要有效的干预措施来改善转移性EGC患者的预后。本研究评估了早期跨学科支持治疗整合对转移性EGC患者的总体生存率(OS)的影响。

胃食管癌(EGC)是全球癌症相关死亡的第二大主要原因。当下,迫切需要有效的干预措施来改善转移性EGC患者的预后。本研究评估了早期跨学科支持治疗整合对转移性EGC患者的总体生存率(OS)的影响。

这是一项在北京大学肿瘤医院开展的开放性随机对照3期试验,招募了既往未治疗过的转移性EGC患者,按2:1随机分至早期跨学科支持治疗联合标准治疗(ESC)组或标准治疗(EC)组。ESC组患者接受由胃肠内科肿瘤专家、肿瘤护理专家、营养师和心理学家共同治疗;SC组患者接受仅标准的肿瘤治疗。主要终点是OS。

研究流程

2015年4月16日-2017年12月29日,共招募了328位患者:214位分至ESC组,114位分至SC组。截止2019年1月26日,有15位(5%)患者失访。

主要预后

ESC组的一线化疗的中位疗程为5个(IQR 4-7),SC组的为4个(IQR 2-6)。ESC组和SC组的中位OS分别是14.8个月(95% CI 13.3-16.3)和11.9个月(9.6-13.6;HR 0.68,95% CI 0.51-0.9;P=0.021)

亚组预后

该研究表明,跨学科支持治疗的早期整合增加转移性胃癌患者的生存益处。未来值得进一步进行优化和标准化研究探索。

原始出处:

Zhihao Lu, et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. Journal of Clinical Oncology. January 07, 2020.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
    2021-07-16 lidong40
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2040408, encodeId=11c820404080d, content=<a href='/topic/show?id=1f61229925d' target=_blank style='color:#2F92EE;'>#临床获益#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22992, encryptionId=1f61229925d, topicName=临床获益)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a57b78, createdName=朱睿睿, createdTime=Mon Nov 08 09:19:21 CST 2021, time=2021-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1891623, encodeId=422e189162397, content=<a href='/topic/show?id=25b0102e2df' target=_blank style='color:#2F92EE;'>#JCO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10272, encryptionId=25b0102e2df, topicName=JCO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6da1120, createdName=lidong40, createdTime=Fri Jul 16 15:19:21 CST 2021, time=2021-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1735296, encodeId=47041e35296c9, content=<a href='/topic/show?id=de4d9343316' target=_blank style='color:#2F92EE;'>#转移性胃癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93433, encryptionId=de4d9343316, topicName=转移性胃癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e6333886015, createdName=limedical1985, createdTime=Mon Sep 20 15:19:21 CST 2021, time=2021-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1723410, encodeId=07c71e23410fa, content=<a href='/topic/show?id=98448285477' target=_blank style='color:#2F92EE;'>#肿瘤医院#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82854, encryptionId=98448285477, topicName=肿瘤医院)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bb3833453694, createdName=yulin2017, createdTime=Thu Sep 02 03:19:21 CST 2021, time=2021-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1313816, encodeId=8d70131381687, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80712, encryptionId=d4cc80e128f, topicName=联合治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386690, encodeId=1a0f1386690cf, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1531331, encodeId=5d6a15313311c, content=<a href='/topic/show?id=4683129675' target=_blank style='color:#2F92EE;'>#3期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1296, encryptionId=4683129675, topicName=3期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=06eb12252541, createdName=zexyw05, createdTime=Thu Jan 14 11:19:21 CST 2021, time=2021-01-14, status=1, ipAttribution=)]

相关资讯

Clin Cancer Res:二代紫杉烷卡巴他赛治疗转移性胃癌的疗效

本研究是一项多中心的II期临床试验,旨在研究一种新型二代紫杉类药物卡巴他赛(cabazitaxel)治疗转移性胃癌的疗效和安全性。

PD-1单抗三线治疗转移性胃癌,推荐等级“更上一层楼”

近期,2019年CSCO指南发布大会在南京召开。结合最新的研究证据,多个瘤种指南与时俱进,进行了更新,对临床实践意义重大。尤其是近一年来,免疫治疗取得了重大进展,在各大肿瘤治疗中均得到推荐。在2019年CSCO胃癌诊疗指南中,关于免疫治疗的相关推荐进行了更新,从Ⅲ级推荐提升为Ⅱ级推荐。特邀北京协和医院的白春梅教授为大家重点介绍CSCO胃癌诊疗指南中转移性胃癌免疫治疗更新要点,并梳理其背后的研究证据